For the Inventor, By the Inventor

Enter assignee name

Gyeonggi, South Korea

Korea Greencross Corporation

USPTO Granted Patents = 16

% Expired Patents = 18.8

Forward Citations = 176

Loading Chart...

Loading Chart...

65 inventors (with patents filed for the assignee):

Chil-Yong Kang (2 out of 10 patents)

Lizhong Luo (2 out of 2 patents)

Young Ae Joe (1 out of 4 patents)

4. Sang Hoon Paik (1 out of 5 patents)

5. Jae Wook Huh (1 out of 2 patents)

6. Jean Man Kim (1 out of 3 patents)

7. Young Chul Sung (1 out of 25 patents)

8. Myeong-Hee Yu (1 out of 2 patents)

9. Hee-Sook Jun (1 out of 6 patents)

10. Chi Bom Chae (1 out of 1 patent)

11. Dong Goo Bae (1 out of 1 patent)

12. Wan Hee Yoon (1 out of 1 patent)

13. Chun Jeih Ryu (1 out of 1 patent)

14. Hyo Jeong Hong (1 out of 1 patent)

15. Hyangsuk Hur (1 out of 1 patent)

16 patents: Sort by Forward Citations

1. 7291601 - Arginine-rich anti-vascular endothelial growth factor peptides that inhibit growth and metastasis of human tumor cells by blocking angiogenesis (2007-11-06),

2. 7115723 - Humanized antibody specific for surface antigen pre-S1 of HBV and preparation method thereof (2006-10-03),

3. 6991792 - Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase (2006-01-31),

4. 6887852 - Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer (2005-05-03),

5. 6770457 - Process of purifying angiogenesis inhibitors (2004-08-03),

6. 6454739 - Fibrin sealant delivery device (2002-09-24),

7. 6406874 - Method of determining the enzymatic activity of the blood coagulation factor XIII using purified fibrin monomer as a substrate (2002-06-18),

8. 5843773 - Apoptosis regulating gene (1998-12-01),

9. 5837494 - E. coli mutant with suppressed organic acid production (1998-11-17),

10. 5817484 - Thermoresistant .alpha.-1-antitrypsin mutein (1998-10-06),

11. 5580773 - Chimeric immunogenic gag-V3 virus-like particles of the human (1996-12-03),

12. 5443828 - Chimeric HIV-2 gag particles (1995-08-22),

13. 5346696 - Asialoglycoprotein - conjugated medicinal agent (1994-09-13),

14. 5244662 - Medicinal extract from a mixture of Phellodendron and defatted seed of (1993-09-14),

15. 5183658 - Hantaan virus strain ROK84/105 and vaccine therefor (1993-02-02),

Company Overview

Korea Greencross Corporation is a prominent biopharmaceutical company based in Gyeonggi, South Korea. The organization specializes in the development and manufacturing of innovative vaccines, therapeutic proteins, and biosimilars, focusing on enhancing healthcare solutions. With a commitment to research and development, Greencross aims to address various medical needs through advanced biotechnological processes. The company plays a significant role in the global biopharmaceutical landscape, contributing to the advancement of health and wellness.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

16 Patents

#5 in Gyeonggi

#745 in South Korea

#37,831 in the World

Gyeonggi, South Korea

Korea Greencross Corporation

Forward Citations = 176

65 inventors:

Chil-Yong Kang (2 out of 10 patents)

Lizhong Luo (2 out of 2 patents)

Young Ae Joe (1 out of 4 patents)

4. Sang Hoon Paik (1 out of 5 patents)

5. Jae Wook Huh (1 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Korea Greencross Corporation. Retrieved from https://idiyas.com/company/korea-greencross

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…